Consensus Statement Supported by NAAF Through Student Internship Award Recipient New international expert consensus recommendations provide healthcare providers with practical…
Yagiz Matthew (Matt) Akiska, MD, MPH, answers questions from NAAF about the consensus statement on the use of minoxidil in…
New indication gives adolescents ages 12 and older another FDA-approved treatment option for severe alopecia areata The U.S. Food and…
Open enrollment is an important opportunity to review your health insurance coverage. And, if you or a family member is living…
For people with alopecia areata who have been prescribed a JAK inhibitor, getting the prescription may be only the first…
Yesterday, the first U.S. expert consensus treatment recommendations for adults with severe alopecia areata were published in JAMA Dermatology. Developed…
The National Alopecia Areata Foundation (NAAF) is thrilled to announce that it has welcomed Ryan Reczek as its President &…
Findings from two Phase 3 clinicals trial published in JAMA Dermatology found that upadacitinib (Rinvoq®), an oral Janus kinase (JAK)…
A generic version of Xeljanz® (tofacitinib) is now available in the United States, with prices reported as low as $25–$150…
Q32 Bio has announced positive 36-week topline results from Part B of its Phase 2 SIGNAL-AA clinical trial evaluating bempikibart,…
